SCHEMBL7879136

SCHEMBL7879136

CC(C)(C)c1ccc(OCCO)c(C(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.47
MAPK1 P28482 3/20 0.45
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
CYP3A4 P08684 1/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP2C19 P33261 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
LMNA P02545 3/20 0.42
RECQL P46063 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
THRA P10827 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386379 0.92 KDM4E (0.44) KDM4EMAPK1MAPTNPSR1TRPV1
SCHEMBL347184 0.92 KDM4E (0.44) KDM4EMAPK1MAPTNPSR1TRPV1
SCHEMBL4801925 0.92 KDM4E (0.46) KDM4EMAPK1MAPTNPSR1TRPV1
SCHEMBL14097237 0.91 KDM4E (0.48) KDM4EMAPK1MAPTNPSR1TRPV1
SCHEMBL12139610 0.89 S1PR1 (0.44) KDM4EMAPK1MAPTNPSR1SMN1; SMN2
SCHEMBL31074354 0.87 SMN1; SMN2 (0.40) KDM4EMAPK1MAPTNPSR1TRPV1
SCHEMBL25791644 0.86 KDM4E (0.44) KDM4EMAPK1MAPTNPSR1GAA
SCHEMBL11357426 0.86 KDM4E (0.50) KDM4EMAPK1MAPTNPSR1GAA
SCHEMBL17708050 0.84 KDM4E (0.66) KDM4EMAPK1MAPTNPSR1SMN1; SMN2
SCHEMBL986849 0.84 KDM4E (0.49) KDM4EMAPK1MAPTNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6174503-B1 NUCLEAR WASTES TREATMENT, ESPECIALLY WASTES WITH A HIGH CONCENTRATION OF COMPETING ALKALI METAL CATIONS LOCKHEED MARTIN ENERGY RESEARCH CORPORATION 2001-01-16 US claimed
WO-1999012878-A1 SOLVENT AND PROCESS FOR EXTRACTING CESIUM FROM ALKALINE WASTE SOLUTIONS LOCKHEED MARTIN ENERGY RES COR (US) 1999-03-18 WO claimed
US-20260078407-A1 RAAV Vectors for the Treatment of GM1 and GM2 Gangliosidosis UNIV MASSACHUSETTS (US) 2026-03-19 US disclosed
EP-4612290-A1 METHODS AND KITS FOR ISOLATING TARGET NUCLEIC ACIDS BELOW A TARGET SIZE FROM A SAMPLE Phase Scientific International, Ltd. (HK) 2025-09-10 EP disclosed
EP-4612288-A1 METHODS FOR ISOLATING TARGET ANALYTES FROM BIOLOGICAL SAMPLES USING ATPS AND SOLID PHASE MEDIA Phase Scientific International, Ltd. (HK) 2025-09-10 EP disclosed
EP-4612289-A1 METHODS, COMPOSITIONS AND KITS FOR CONCENTRATING TARGET ANALYTES FROM A BULK FLUID SAMPLE Phase Scientific International, Ltd. (HK) 2025-09-10 EP disclosed
WO-2024213654-A1 GENTLE METHOD FOR PRODUCING TRANSPARENT BIOLOGICAL PREPARATIONS FOR EXAMINATION BY LIGHT MICROSCOPY GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS (UNIVERSITÄTSMEDIZIN) (DE) 2024-10-17 WO disclosed
WO-2024093522-A1 METHODS, COMPOSITIONS AND KITS FOR CONCENTRATING TARGET ANALYTES FROM A BULK FLUID SAMPLE Phase Scientific International, Ltd. (CN) 2024-05-10 WO disclosed
WO-2024093519-A1 METHODS FOR ISOLATING TARGET ANALYTES FROM BIOLOGICAL SAMPLES USING ATPS AND SOLID PHASE MEDIA Phase Scientific International, Ltd. (CN) 2024-05-10 WO disclosed
US-20240019420-A1 METHODS AND COMPOSITIONS FOR ISOLATION AND RAPID DETECTION OF MICRO-ORGANISMS FROM BLOOD AND BODILY FLUIDS ACUTIS DIAGNOSTICS, INC. (US) 2024-01-18 US disclosed
US-20240011012-A1 METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION PFIZER (US) 2024-01-11 US disclosed
US-20230390463-A1 TISSUE SCAFFOLDS JD BIOMEDICAL SOLUTIONS LTD (GB) 2023-12-07 US disclosed
CN-116867902-A Methods and compositions for inhibiting precipitation of excess nucleic acid 辉瑞公司 2023-10-10 CN disclosed
US-20130187095-A1 THERMOSETTING ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-07-25 US disclosed
US-20130187095-A1 THERMOSETTING ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-07-25 US disclosed
US-20130187095-A1 THERMOSETTING ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-07-25 US disclosed
US-6174503-B1 NUCLEAR WASTES TREATMENT, ESPECIALLY WASTES WITH A HIGH CONCENTRATION OF COMPETING ALKALI METAL CATIONS LOCKHEED MARTIN ENERGY RESEARCH CORPORATION 2001-01-16 US disclosed
WO-1999012878-A1 SOLVENT AND PROCESS FOR EXTRACTING CESIUM FROM ALKALINE WASTE SOLUTIONS LOCKHEED MARTIN ENERGY RES COR (US) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078407-A1 RAAV Vectors for the Treatment of GM1 and GM2 Gangliosidosis GALC, HEXB, MAN2B1 KDM4E 1721/4885MAPK1 3158/4885MAPT 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.